Effects of Monoclonal Antibodies against Human Stathmin Combined with Paclitaxel on Proliferation of the QG-56 Human Lung Carcinoma Cell Line

Yuan, Shengtao; Zhu, Lijun; Zheng, Weihua; Chen, Hua; Xiong, Jianping

doi:10.7314/apjcp.2012.13.6.2967

Cited by 7 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…And inhibition of Rlim (a Ring H2 zinc finger protein) increases the expression of stathmin, and leads to cell proliferation of human osteosarcoma cell lines [ 53 ]. Monoclonal antibodies against stathmin and paclitaxel have bee used alone or incombination to inhibit the proliferation of human lung carcinoma QG-56 cells, especially result in a significant apoptosis [ 54 ]. A novel tumor-specific RNA interference adenovirus system targeting Aurora A by using stathmin promoter not only inhibits the cells proliferation, but also enhance the chemosensitivity to paclitaxel in human breast carcinoma SK-BR-3 and MDA-MB-231 cells, and further decreases the phosphatidylinositol 3 kinase/Akt and p-BRCA1 protein expression [ 55 ].…”

Section: Introductionmentioning

confidence: 99%

“…For instance, knockdown of stathmin significantly reduces pancreatic cancer cell viability, colony formation, and even retards pancreatic tumor growth in nude mice [ 27 ].Although leukemia is not a solid tumor, stathmin silencing still reduces cell proliferation and clonogenicity of U937 and Namalwa leukemia cells [ 66 ]. More widely, siRNA-mediated silencing of stathmin has been shown to suppress the proliferation, invasion and metastasis of nasopharyngeal carcinoma (NPC) cells [ 60 ], hepatoma [ 4 ], retinoblastoma [ 86 ], endometrial carcinoma [ 33 ], bladder cancer [ 36 ] and glioma [ 89 ], and significantly induces the apoptosis of tumor cells [ 54 , 60 , 62 ]. Adenovirus-mediated gene transfer of anti-stathmin ribozyme inhibits cell proliferation and clonogenicity in both ER-positive and ER-negative breast cancer cells [ 48 ] and knockdown of stathmin can attenuate the miR-101-mediated enhancement of cell growth and metastasis [ 77 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

et al. 2016

View full text Add to dashboard Cite

Knowledge of the molecular mechanisms on malignant tumors is very critical for the development of new treatment strategies like molecularly targeted therapies. In last 5 years, many investigations suggest that stathmin is over-expressed in a variety of human malignant tumors, and potentially promotes the occurrence and development of tumors. Rather, down-regulation of stathmin can reduce cell proliferation, motility and metastasis and induce apoptosis of malignant tumors. Thus, a stathmin antagonist, such as a specific inhibitor (antibody, small molecule compound, peptide, or siRNA), may be a novel strategy of molecular targeted therapy. This review summarizes the research progress of recent 5 years on the role of stathmin in tumorigenesis, the molecular mechanisms and development of anti-stathmin treatment, which suggest that continued investigations into the function of stathmin in the tumorigenesis could lead to more rationally designed therapeutics targeting stathmin for treating human malignant tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Effective inhibition of stathmin expression in malignant tumors suppresses tumor cell division and proliferation, and also promotes cell apoptosis and collaborates with anti-microtubule drugs to produce an antitumor effect (3). Stathmin is likely to be a promising therapeutic target in tumor treatment (4,5). …”

Section: Introductionmentioning

confidence: 99%

Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Jiang¹,

Xiao-fang³

et al. 2013

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of this study was to explore the correlation between mRNA expression of β-tubulin-III and stathmin in patients with stage II non-small cell lung cancer (NSCLC) and the chemosensitivity to Navelbine plus cisplatin (NP), as well as to provide a basis for personalized treatment. A single-gene quantitative test was performed to detect the mRNA expression of β-tubulin-III and stathmin in the tumor tissue of patients with stage II NSCLC. All the patients underwent NP treatment following surgery and were followed-up to record their disease-free survival (DFS) and overall survival (OS). Statistical analyses were conducted to investigate the correlation between β-tubulin-III and stathmin mRNA expression and DFS and OS in the patients. β-tubulin-III mRNA expression was associated with OS in the 73 patients (P=0.003) and DFS was correlated with β-tubulin-III mRNA expression and lymphatic metastasis (P<0.01). Stathmin mRNA expression was not correlated with OS or DFS (P>0.05). OS and DFS were longer in the patients with low β-tubulin-III mRNA expression than in those with high β-tubulin-III mRNA expression (P<0.01); there was no significant change in OS and DFS between the patients with high and low mRNA expression of stathmin (P>0.05). The mRNA expression levels of β-tubulin-III in the tumor tissue of patients with stage II NSCLC may be considered as an index of prognosis and chemosensitivity, as well as a reference for personalized chemotherapeutic applications in patients.

show abstract

“…For instance, STMN is associated with the proliferation, differentiation and metastasis of cancers (33). High levels of STMN expression are required for maintaining high proliferation rates in tumor cells (34). A previous study also concluded that high STMN expression was significantly associated with tumor invasion and TNM clinical classification in esophageal carcinoma (9).…”

Section: Discussionmentioning

confidence: 98%

Stathmin gene silencing suppresses proliferation, migration and invasion of gastric cancer cells via AKT/sCLU and STAT3 signaling

et al. 2019

View full text Add to dashboard Cite

Globally, gastric cancer is the fifth most common malignancy, with high rates of incidence and mortality. The high mortality rate and poor prognosis of gastric cancer are closely associated with its profound invasiveness, high incidence of metastasis, rapid proliferation, and high rate of recurrence. Previous studies have confirmed that stathmin (STMN) has an important role in the occurrence, development and prognosis of gastric cancer. However, the detailed mechanisms by which STMN affects these processes remain unclear. The aim of the present study was to determine how STMN promotes invasion, migration and proliferation in gastric cancer tumor cells. The results of immunohistochemistry indicated that STMN is overexpressed in stomach neoplasm tissues, and that it is associated with migration, invasion, proliferation and anti-apoptotic states of gastric cancer cells. The secretory proteins of gastric cancer cells with or without STMN knockdown were further analyzed using the isobaric tags for relative and absolute quantitation method to identify differentially expressed proteins verified by reverse transcription-quantitative polymerase chain reaction and western blot analysis. Inhibition of STMN decreases the levels of clusterin, cystatin C and matrix metalloproteinases, followed by inhibiting the protein kinase B and signal transducer and activation of transcription activation. These findings suggest that STMN could be a promising therapeutic target for gastric cancer.

show abstract

Effects of Monoclonal Antibodies against Human Stathmin Combined with Paclitaxel on Proliferation of the QG-56 Human Lung Carcinoma Cell Line

Cited by 7 publications

References 17 publications

Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years’ discoveries and developments

Correlation between microtubule-associated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer

Stathmin gene silencing suppresses proliferation, migration and invasion of gastric cancer cells via AKT/sCLU and STAT3 signaling

Contact Info

Product

Resources

About